Gyala Therapeutics
PrivateLast Round
Grant
Feb 11, 2026
Total Funding Raised
$9.64M
Company Overview
Gyala Therapeutics operates in Healthcare & Life Sciences and is based in Barcelona. Its latest recorded funding round was a Grant round in February 2026.
Gyala Therapeutics is a biotechnology company developing next-generation immunotherapies for hematological cancers with high unmet need.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2G
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gyala Therapeutics Comparables
Compare Gyala Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OneChain Immunotherapeutics | 86% | |
| iCell Gene Therapeutics | 76% | |
| AvenCell | 73% |
For institutional investors. Book with your work email.
Gyala Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 11, 2026 | ||||
| Seed | Sep 15, 2025 | ||||
| VC Round | Oct 14, 2024 | ||||
| Seed | May 26, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Gyala Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Nara Capital | VC Round, Seed |
| Center for Technological Development and Innovation | VC Round, Seed |
| Invivo Partners | VC Round, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2025
First-in-class therapy targets CD84, showing preclinical efficacy in leukemias.
- Sep 15, 2025
$4M raised from Invivo Partners and Nara Capital.
For institutional investors. Book with your work email.
Gyala Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gyala Therapeutics's valuation, stock price, and market status.
Is Gyala Therapeutics a public or private company?
Gyala Therapeutics is a private company.
What is the current stock price of Gyala Therapeutics?
Gyala Therapeutics is a private company, so its shares have no public market price. Caplight tracks Gyala Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gyala Therapeutics worth (valuation)?
Valuation information for Gyala Therapeutics is not publicly available.
Can I buy Gyala Therapeutics stock?
Gyala Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gyala Therapeutics's last funding round?
Gyala Therapeutics's most recent funding round was Grant on February 11, 2026.
Who are the main investors in Gyala Therapeutics?
Key investors in Gyala Therapeutics include Nara Capital, Center for Technological Development and Innovation, Invivo Partners.
Will Gyala Therapeutics IPO soon?
No public IPO plans have been announced for Gyala Therapeutics.
How can I track Gyala Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Gyala Therapeutics's shares on secondary markets.